Aratana Therapeutics Inc (NASDAQ:PETX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Aratana Therapeutics Inc (NASDAQ:PETX) have earned an average recommendation of “Hold” from the eight analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $4.73.

Several equities analysts have recently weighed in on the stock. BidaskClub downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 6th. Zacks Investment Research raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 10th.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in Aratana Therapeutics by 1.7% during the second quarter. Bank of New York Mellon Corp now owns 169,284 shares of the biopharmaceutical company’s stock worth $874,000 after purchasing an additional 2,829 shares during the period. Parallel Advisors LLC raised its stake in Aratana Therapeutics by 55.6% during the second quarter. Parallel Advisors LLC now owns 14,000 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 5,000 shares during the period. Bank of America Corp DE raised its stake in Aratana Therapeutics by 21.5% during the fourth quarter. Bank of America Corp DE now owns 38,391 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 6,803 shares during the period. BNP Paribas Arbitrage SA raised its stake in Aratana Therapeutics by 64,346.7% during the first quarter. BNP Paribas Arbitrage SA now owns 9,667 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 9,652 shares during the period. Finally, Aperio Group LLC purchased a new position in Aratana Therapeutics during the second quarter worth about $51,000. 65.00% of the stock is currently owned by hedge funds and other institutional investors.

PETX remained flat at $$4.92 during midday trading on Friday. The firm has a market capitalization of $241.08 million, a PE ratio of -15.38 and a beta of 1.40. Aratana Therapeutics has a 1-year low of $3.30 and a 1-year high of $7.16. The company has a fifty day moving average price of $4.92 and a 200 day moving average price of $4.58.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

See Also: Why does a company issue an IPO?

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.